Home

Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for new one-month of dual-antiplatelet therapy (DAPT) labelling with an expanded indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx drug-eluting stent (DES). The Resolute Onyx DES is the first-and-only DES in the USA that has been proven safe and effective utilising a one-month regimen of DAPT—the combination of aspirin and an anticoagulant—following a percutaneous coronary intervention (PCI) in patients at high bleeding risk.

Patients that are at risk for high bleeding include older patients, those with history of bleeding, or those on oral blood-thinning drugs, and account for up to 40% of PCI patients. Clinical studies have demonstrated that Resolute Onyx DES and its biocompatible polymer and stent design promote fast vessel healing and is well-suited for patients who may benefit from a DAPT duration as short as one month.

“It is so rewarding to see the efforts of those involved in examining the safety and efficacy of one-month of DAPT following PCI—the coordinators, investigators and most importantly the Onyx One Clear patient participants—come to fruition with this new high bleeding risk indication for the Resolute Onyx drug eluting stent,” said Ajay Kirtane, professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, New York, USA) and principal investigator for the Onyx One Clear study. ”It is remarkable how the combination of technology innovation, in conjunction with the generation of clinical evidence, has informed our understanding that shorter durations of DAPT may in fact be safe in appropriately selected patients treated with Resolute Onyx DES.”

Using a broad criteria for HBR, the approval is based on results from the Onyx ONE Clear Study that evaluated approximately 1,500 complex HBR patients on one-month DAPT treated with Resolute Onyx. At one year, the study met its primary endpoint of cardiac death or myocardial infarction and showed Resolute Onyx to be safe and effective in HBR patients on one-month DAPT. Results from the study were shared virtually in March at the American College of Cardiology together with the World Congress of Cardiology Scientific Sessions (ACC.20/WCC). The Onyx ONE Clear study, coupled with the Onyx ONE Global study, make up the Onyx ONE Month DAPT Program that supports the advancement of DAPT evidence, initiated by physicians and Medtronic.

“The journey leading to an HBR indication has included years of rigorous clinical evaluation with more than 22,000 complex patients studied,” said Dave Moeller, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic. “We are excited to realise our goal of providing physicians with more robust data and a supporting indication to inform treatment decisions for HBR patients, who may be suitable for a one-month course of DAPT.”

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Medtronic’s Resolute Onyx approved for one-month DAPT labelling by US FDA

Chia sẽ qua google bài: Medtronic’s Resolute Onyx approved for one-month DAPT labelling by US FDA

Chia sẽ qua twitter bài: Medtronic’s Resolute Onyx approved for one-month DAPT labelling by US FDA

Chia sẽ qua MySpace bài: Medtronic’s Resolute Onyx approved for one-month DAPT labelling by US FDA

Chia sẽ qua LinkedIn bài: Medtronic’s Resolute Onyx approved for one-month DAPT labelling by US FDA

Chia sẽ qua stumbleupon bài: Medtronic’s Resolute Onyx approved for one-month DAPT labelling by US FDA

Chia sẽ qua icio bài: Medtronic’s Resolute Onyx approved for one-month DAPT labelling by US FDA

Chia sẽ qua digg bài: Medtronic’s Resolute Onyx approved for one-month DAPT labelling by US FDA

Chia sẽ qua yahoo bài: Medtronic’s Resolute Onyx approved for one-month DAPT labelling by US FDA

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.